Toronto, Ontario–(Newsfile Corp. – December 14, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the appointment of Paul Carter, former Chief Commercial Officer of Gilead Sciences Inc., as an independent member of its Board of…


Previous articlePT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative Financing Vine
Next articleEditor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity